Sequence Bio Founder and CEO Dr. Tyler Wish Named Canadian Innovation Leader

ST. JOHN'S, June 15, 2016 /CNW/ - Dr. Tyler Wish, founder and CEO of Newfoundland and Labrador biotechnology company Sequence Bio, has been named to a team of Canadian innovators by the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development. The Honourable Kirsty Duncan, Minister of Science, and the Honourable Bardish Chagger, Minister of Small Business and Tourism, will work with Minister Bains as part of the Government of Canada Innovation Agenda.

"Canada is full of bright minds and big ideas and I'm proud to help drive the innovation agenda forward with other passionate leaders from coast to coast. I applaud Minister Bains and the Government of Canada for their leadership in this area. This is a bold move: collaborative innovation and entrepreneurship is critical to a more prosperous, productive future", said Dr. Wish. 

These leaders represent the private sector, universities and colleges, the not-for-profit sector, social entrepreneurs and businesses owned and operated by Indigenous people. During the summer of 2016, each leader will host a series of roundtable discussions to bring together relevant stakeholders for action-focused sessions. This September the Innovation Leaders will meet with Minister Bains in Waterloo to discuss the findings and their perspectives following the engagement series.

"Canada needs more well-rounded leaders, such as Dr. Wish, who successfully navigate between the worlds of science and business. Our country should celebrate the contributions of those who not only contribute to discovery-based research, but also work to turn those ideas into solutions that benefit all Canadians", noted the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development.

Sequence Bio is a biotechnology company leading a 100,000 person population sequencing initiative in the Province of Newfoundland & Labrador. The initiative will generate a uniquely powerful dataset of genomic and phenotypic information that will be used for computational drug discovery and to empower better patient care. SequenceBio is committed to working with participants, collaborators and partners to enable innovation that enhances the lives of patients, families and communities in Newfoundland & Labrador and around the world. Please visit www.sequencebio.co for additional corporate, investor and participant information. 

For additional information on Sequence Bio, please visit www.Sequencebio.ca; view Governement of Canada info here

SOURCE Sequence Bio

Karen Moores, VP Public Affairs and Communications, [email protected], 709.697.0734